Long‐term weight control study II (weeks 34 to 104): An open‐label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

Michael Weintraub, Pavur R. Sundaresan, Barbara Schuster, Gerald Ginsberg, Manish Madan, Andrew Balder, E. Carol Stein, Louise Byrne

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open‐label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo‐to‐active group). Those receiving fenfluramine plus phentermine between weeks 6 and 34 either continued to receive medication or began targeted intermittent therapy. Participants who did not lose 10% of initial weight received an augmented dose (60 mg fenfluramine plus 30 mg phentermine. The placebo‐to‐active group lost an additional 9.1 ± 0.8 kg (mean ± SEM) in the period from week 34 to week 60. At week 60, they were assigned to either continue medication, intermittent therapy, or augmented therapy. More than 68% (83) of the original participants completed up to study week 104. At that point, overall weight loss was 10.8 ± 0.7 kg (11.6 ± 0.8% of initial weight); participants who continued to receive fenfluramine plus phentermine lost 11.6 ± 0.8 kg, participants receiving intermittent therapy lost 11.6 ± 1.3 kg, and participants receiving augmented therapy lost 6.5 ± 1.5 kg. Although 41% of the participants complained of dry mouth, neither serious adverse effects nor evidence of medication abuse appeared. There were 29 dropouts in the period from weeks 34 to 104. Sixteen of those were related to medication (adverse effects, lack of efficacy, and fear of medication). Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise continued to be efficacious for up to 2 years. Clinical Pharmacology and Therapeutics (1992) 51, 595–601; doi:

Original languageEnglish (US)
Pages (from-to)595-601
Number of pages7
JournalClinical Pharmacology & Therapeutics
Volume51
Issue number5
DOIs
StatePublished - Jan 1 1992

Fingerprint

Phentermine
Fenfluramine
Caloric Restriction
Behavior Therapy
Weights and Measures
Therapeutics
Clinical Pharmacology
Fear
Mouth
Weight Loss
Placebos

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Long‐term weight control study II (weeks 34 to 104) : An open‐label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. / Weintraub, Michael; Sundaresan, Pavur R.; Schuster, Barbara; Ginsberg, Gerald; Madan, Manish; Balder, Andrew; Stein, E. Carol; Byrne, Louise.

In: Clinical Pharmacology & Therapeutics, Vol. 51, No. 5, 01.01.1992, p. 595-601.

Research output: Contribution to journalArticle

Weintraub, Michael ; Sundaresan, Pavur R. ; Schuster, Barbara ; Ginsberg, Gerald ; Madan, Manish ; Balder, Andrew ; Stein, E. Carol ; Byrne, Louise. / Long‐term weight control study II (weeks 34 to 104) : An open‐label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. In: Clinical Pharmacology & Therapeutics. 1992 ; Vol. 51, No. 5. pp. 595-601.
@article{b8c87a7efb644fa18f4d0aa0d8b7917f,
title = "Long‐term weight control study II (weeks 34 to 104): An open‐label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise",
abstract = "Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open‐label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo‐to‐active group). Those receiving fenfluramine plus phentermine between weeks 6 and 34 either continued to receive medication or began targeted intermittent therapy. Participants who did not lose 10{\%} of initial weight received an augmented dose (60 mg fenfluramine plus 30 mg phentermine. The placebo‐to‐active group lost an additional 9.1 ± 0.8 kg (mean ± SEM) in the period from week 34 to week 60. At week 60, they were assigned to either continue medication, intermittent therapy, or augmented therapy. More than 68{\%} (83) of the original participants completed up to study week 104. At that point, overall weight loss was 10.8 ± 0.7 kg (11.6 ± 0.8{\%} of initial weight); participants who continued to receive fenfluramine plus phentermine lost 11.6 ± 0.8 kg, participants receiving intermittent therapy lost 11.6 ± 1.3 kg, and participants receiving augmented therapy lost 6.5 ± 1.5 kg. Although 41{\%} of the participants complained of dry mouth, neither serious adverse effects nor evidence of medication abuse appeared. There were 29 dropouts in the period from weeks 34 to 104. Sixteen of those were related to medication (adverse effects, lack of efficacy, and fear of medication). Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise continued to be efficacious for up to 2 years. Clinical Pharmacology and Therapeutics (1992) 51, 595–601; doi:",
author = "Michael Weintraub and Sundaresan, {Pavur R.} and Barbara Schuster and Gerald Ginsberg and Manish Madan and Andrew Balder and Stein, {E. Carol} and Louise Byrne",
year = "1992",
month = "1",
day = "1",
doi = "10.1038/clpt.1992.70",
language = "English (US)",
volume = "51",
pages = "595--601",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Long‐term weight control study II (weeks 34 to 104)

T2 - An open‐label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

AU - Weintraub, Michael

AU - Sundaresan, Pavur R.

AU - Schuster, Barbara

AU - Ginsberg, Gerald

AU - Madan, Manish

AU - Balder, Andrew

AU - Stein, E. Carol

AU - Byrne, Louise

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open‐label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo‐to‐active group). Those receiving fenfluramine plus phentermine between weeks 6 and 34 either continued to receive medication or began targeted intermittent therapy. Participants who did not lose 10% of initial weight received an augmented dose (60 mg fenfluramine plus 30 mg phentermine. The placebo‐to‐active group lost an additional 9.1 ± 0.8 kg (mean ± SEM) in the period from week 34 to week 60. At week 60, they were assigned to either continue medication, intermittent therapy, or augmented therapy. More than 68% (83) of the original participants completed up to study week 104. At that point, overall weight loss was 10.8 ± 0.7 kg (11.6 ± 0.8% of initial weight); participants who continued to receive fenfluramine plus phentermine lost 11.6 ± 0.8 kg, participants receiving intermittent therapy lost 11.6 ± 1.3 kg, and participants receiving augmented therapy lost 6.5 ± 1.5 kg. Although 41% of the participants complained of dry mouth, neither serious adverse effects nor evidence of medication abuse appeared. There were 29 dropouts in the period from weeks 34 to 104. Sixteen of those were related to medication (adverse effects, lack of efficacy, and fear of medication). Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise continued to be efficacious for up to 2 years. Clinical Pharmacology and Therapeutics (1992) 51, 595–601; doi:

AB - Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open‐label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo‐to‐active group). Those receiving fenfluramine plus phentermine between weeks 6 and 34 either continued to receive medication or began targeted intermittent therapy. Participants who did not lose 10% of initial weight received an augmented dose (60 mg fenfluramine plus 30 mg phentermine. The placebo‐to‐active group lost an additional 9.1 ± 0.8 kg (mean ± SEM) in the period from week 34 to week 60. At week 60, they were assigned to either continue medication, intermittent therapy, or augmented therapy. More than 68% (83) of the original participants completed up to study week 104. At that point, overall weight loss was 10.8 ± 0.7 kg (11.6 ± 0.8% of initial weight); participants who continued to receive fenfluramine plus phentermine lost 11.6 ± 0.8 kg, participants receiving intermittent therapy lost 11.6 ± 1.3 kg, and participants receiving augmented therapy lost 6.5 ± 1.5 kg. Although 41% of the participants complained of dry mouth, neither serious adverse effects nor evidence of medication abuse appeared. There were 29 dropouts in the period from weeks 34 to 104. Sixteen of those were related to medication (adverse effects, lack of efficacy, and fear of medication). Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise continued to be efficacious for up to 2 years. Clinical Pharmacology and Therapeutics (1992) 51, 595–601; doi:

UR - http://www.scopus.com/inward/record.url?scp=0026593857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026593857&partnerID=8YFLogxK

U2 - 10.1038/clpt.1992.70

DO - 10.1038/clpt.1992.70

M3 - Article

C2 - 1587073

AN - SCOPUS:0026593857

VL - 51

SP - 595

EP - 601

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -